Monday, 6 October 2014

Abzymes....antibodies that degrade myelin in the CSF and Blood of MSers

Doronin VB, Parkhomenko TA, Castellazzi M, Padroni M, Pastore M, Buneva VN, Granieri E, Nevinsky GA.Comparison of Antibodies Hydrolyzing Myelin Basic Protein from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis.
PLoS One. 2014 Sep 29;9(9):e107807. doi:10.1371/journal.pone.0107807. eCollection 2014.

It was found that antibodies (Abs) against myelin basic protein (MBP) are the major components of the antibody response in multiple sclerosis (MS) patients. We have recently shown that IgGs from sera of MS patients are active in the hydrolysis of MBP. However, in literature there are no available data concerning possible MBP-hydrolyzing Abs in cerebrospinal fluid (CSF) of MS patients. We have shown that the average content of IgGs in their sera is about 195-fold higher than that in their CSF. Here we have compared, for the first time, the average content of lambda- and kappa-IgGs as well as IgGs of four different subclasses (IgG1-IgG4) in CSF and sera of MS patients. The average relative content of lambda-IgGs and kappa -IgGs in the case of CSFs (8.0 and 92.0%) and sera (12.3 and 87.7%) are comparable, while IgG1, IgG2, IgG3, and IgG4: CSF - 40.4, 49.0, 8.2, and 2.5% of total IgGs, respectively and the sera - 53.6, 36.0, 5.6, and 4.8%, decreased in different order. Electrophoretically and immunologically homogeneous IgGs were obtained by sequential affinity chromatography of the CSF proteins on protein G-Sepharose and FPLC gel filtration. We present first evidence showing that IgGs from CSF efficiently hydrolyze MBP and that their average specific catalytic activity is unpredictably ∼54-fold higher than that of Abs from sera of the same MS patients. Some possible reasons of these findings are discussed. We suggest that anti-MBP abzymes of CSF may promote important neuropathologic mechanisms in this chronic inflammatory disorder and in MS pathogenesis development.






The story of antibodies to myelin in MS is not a new one, in fact both MOG and MBP (anti-MOG antibodies being more prevalent than anti-MBP antibodies) have frequently been studied as the sole targets in the development of MS. 

Whilst considered transient in other inflammatory neurological disorders, these antibody responses persist in MS and may even be established in early MS (forming the basis of oligoclonal band testing in the diagnosis of MS).

However, the novelty here is what exactly these antibodies do. Here, the authors present a novel concept of anti-MBP abzymes. The term ABZYME is derived from antibody and enzyme, which possess their own catalytic activity (i.e. increase the rate of a chemical reaction). In the context of this work, these abzymes appear to lead to the destruction of MBP, which may in turn contribute to the destruction of myelin in the body. This again encourages clinicians and scientists to search for B-cell-mediated contributions to the MS disease process and treatments alike.

2 comments:

  1. What are the thoughts about a drug or procedure that would fully cure MS - would it have to get rid of OCBs or can other mechanisms be blocked without worrying what happens to the OCBs?

    ReplyDelete
  2. Interesting question, I think of OCB's as a barometer of the inflammatory process and it's not a cure until you can get rid of them. There was some buzz about natalizumab clearing OCB's in some instances but this may be a transient response.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.